Trial · NCT03437226
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
NCT03437226, Phase 3, Unknown, Dr. Gerhard Pölzl
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure. Trials, record NCT03437226. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03437226
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
- NCT number
- NCT03437226
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 264 participants, estimated
- Lead sponsor
- Dr. Gerhard Pölzl
- Conditions
- Heart Failure
- Interventions
- Levosimendan 2.5 MG/ML, Placebos
- First posted
- 2018-02-19
- Last updated
- 2018-08-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to death, high-urgent heart transplantation or ventricular assist device (VAD), time to non-fatal HF event | From baseline (day 1) up to Follow-up 2 (day 180) | Time to event in days, from baseline visit (day 1) up to Follow-up 2 (day 180) |
| Primary | Change in NT-proBNP | Change from Baseline NT-proBNP (day 1) to Follow-up 1 (day 90) | pg/ml |
| Secondary | Change in functional status and symptoms via KCCQ (Combined Outcome measurement) | From baseline (day 1) up to day 98 (FUP 1) | KCCQ (Kansas City Cardiomyopathy Questionnaire) The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. |
| Secondary | Change in functional status and symptoms via PGA (Combined Outcome measurement) | From baseline (day 1) up to day 98 (FUP 1) | PGA (Patient's global assessment) |
| Secondary | Change in functional status and symptoms via EQ-5D-5L (Combined Outcome measurement) | From baseline (day 1) up to day 98 (FUP 1) | EQ-5D-5L VAS is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal visual analogue scale |
| Secondary | cumulative number of: days alive out of hospital (Combined Outcome measurement) | From baseline (day 1) up to day 180 (FUP 2) | Counted in days |
| Secondary | cumulative number of: non-fatal HF events (Combined Outcome measurement) | From baseline (day 1) up to day 180 (FUP 2) | Counted in events |
| Secondary | cumulative number of: hospital admissions (Combined Outcome measurement) | From baseline (day 1) up to day 180 (FUP 2) | counted in numbers |
| Secondary | death | From baseline (day 1) to day 180 (FUP 2) | Number of participants died within the defined time points |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | From baseline (day 1) to day 180 (FUP 2) | Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 counted in numbers |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03437226
GET https://conductscience.org/api/trials/v1/NCT03437226/registered